ClinicalTrials.gg
Active, not recruitingNCT05975307BCIRT-01Updated Nov 12, 2026

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation

A Phase 2 interventional study of Toripalimab and Gemcitabine in Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor and Radiotherapy, sponsored by Sun Yat-sen University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Eligibility revisedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing gemcitabine in Urinary Bladder Neoplasms — 12 open to participants now, 23 under way, 3 of them phase 3. Gemcitabine · Urinary Bladder Neoplasms.

Planned enrollment
34th of 96
64 · median 42
Started
2023
with 2 others
Phase 2
61 of 101
7 open now
Primary completion
2026-12
later than 7 of 22 live
Registered
87th of 101
by date

Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, this one is the 34th largest by planned enrollment of the 96 interventional ones that give a count, is one of 3 that started in 2023, is one of 61 in phase 2, reaches primary completion later than 7 of the 22 other live ones, and was the 87th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

12 of the 101 studies testing gemcitabine in Urinary Bladder Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing gemcitabine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment mode which consists of neoadjuvant chemotherapy plus anti-programmed cell death protein 1 (anti-PD-1) therapy followed by radiotherapy plus concurrent anti-PD-1 therapy. The main questions it aims to answer are: (i) whether the anti-PD-1 antibody, toripalimab, is effective in treating muscle-invasive bladder cancer (MIBC), when combined with chemoradiation; (ii) whether toripalimab is safe in combination with chemoradiation. Participants will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy plus 2 cycles of concurrent toripalimab.

Read the detailed description

Bladder cancer is the second most common malignancies over the world. At initial diagnosis, the cases with muscle-invasive bladder cancer (MIBC) accounts nearly 20% of all bladder cancer patients. And 40% of non-muscle-invasive bladder cancer could develop to MIBC. Currently, radical cystectomy (RC) is the golden standard to manage MIBC. Yet, it brings severe surgical injuries and post-surgical complications which impair life quality of the patients. Recently, bladder-preserving treatment based gradually becomes the second choice for MIBC. It consists of maximal transurethral resection of bladder tumor (TURBT) and chemoradiation. A series of clinical trials and meta-analyses supported that the bladder-preserving treatment has a similar therapeutic effect compared with RC. But it is noteworthy that this treatment mode does not really avoid surgery. TURBT could also cause complications, such as haemorrhage, infection, perforation, and even tumor dissemination. Moreover, the incidence of serious toxicities brought by concurrent chemoradiation is as high as 36%. In actual clinical work, it is hard for more than half patients to complete chemoradiation of standard intensity. Additionally, many patients are unsuitable for bladder preservation, including those with T stage > T2, diameter > 5 cm, hydronephrosis and positive lymph nodes. Hence, it calls for improvement of current bladder preservation mode, to make more MIBC patients receive radical treatment which brings better therapeutic experience and life quality.

Many lab studies indicated that formation and progression of bladder cancer is a process of mutation accumulation. It provides biological fundamentals for immune checkpoint inhibitors, such as anti-programmed cell death protein 1 (anti-PD-1) antibodies. Based on available clinical studies, anti-PD-1 antibodies exhibits ideal therapeutic effects in bladder cancer of different stages and has an incidence of toxicities as low as 13%. Its toxicities mainly include arthralgia and hyponatremia, which are well tolerated. Currently, there are more than 10 clinical trials trying anti-PD-1 antibodies for bladder preservation. However, the treatment modes in most of them still contain TURBT. This phase 2 trial intended to evaluate the therapeutic and adverse effects of a non-surgical bladder-preserving treatment mode consisting of anti-PD-1 antibodies and chemoradiation, in a small patient cohort with MIBC. The results might provide an effective, non-invasive and low-toxic choice which improves patient experience and realizes bladder preservation.

03

Conditions studied

  • Muscle-Invasive Bladder Carcinoma
  • Programmed Cell Death Protein 1 Inhibitor
  • Radiotherapy

Keywords

  • Bladder Cancer
  • Programmed Cell Death Protein 1 Inhibitor
  • Radiotherapy
  • Chemotherapy
  • Bladder Preservation
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed bladder malignant tumor via
  • Urothelial carcinoma as the primary histological component
  • Pretreatment clinical TNM stage as T2-4aN0-2M0 (UICC TNM staging classification, version 8)
  • Age between 18 and 75 years old
  • performance score ≥ 70
  • rate ≥ 30 ml/min

Exclusion criteria

Exclusion Criteria:

  • Simultaneous tumors of the urethra or upper urinary tract
  • Existence of small cell cancer component
  • Uncontrolled tuberculosis, viral hepatitis or AIDS
  • or mental diseases
  • Severe cardiac, renal, hepatic or hematopoietic dysfunctions unsuitable for chemotherapy, radiotherapy or immune checkpoint inhibiting therapy
  • Prior history of other within 5 years, except cured cervical carcinoma in situ and skin basal cell carcinoma
  • Prior history of pelvic radiotherapy or chemotherapy
  • Poor adherence to regular follow-up (cystoscopy, CT, MRI, etc.)
  • Pregnant or lactating women
  • Treatment with or drugs within 1 month
  • Other situations for which the investigators consider a patient inappropriate to participate
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Toripalimab plus chemoradiation

    This study has only single arm in which the patients will receive neoadjuvant chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy

    Drug: Toripalimab · Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin · Radiation: Intensity-modulated radiation therapy

Interventions

  • The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab. Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the neoadjuvant and concurrent phases, respectively.

    Also known as: JS001

  • The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab. Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles.

  • The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab. Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.

  • The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab. Carbopatin: Used when creatinine clearance rate 30-39 ml/min, area under curve 4 on Day 1, repeated every 3 weeks, totally 3 cycles.

  • RadiationIntensity-modulated radiation therapy

    The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab. Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions.

06

What researchers measure

Primary outcomes

  1. Clinical complete response (cCR) rate

    The percentage of the cases attaining cCR of primary tumor and regional lymph nodes (confirmed by radiologic examinations, such as thoraco-bdominal computed tomography, pelvic magnetic resonance imaging, and multipoint biopsy under cystoscopy)

    Time frame: When the eligible patients complete the treatment and followed-up for half a year

Secondary outcomes

  1. Overall survival (OS)

    The percentage of the cases surviving over a given time period

    Time frame: When the eligible patients complete the treatment and followed-up for 1 and 2 years

  2. Bladder-intact event-free survival (BI-EFS)

    The percentage of the cases surviving with intact bladder and without muscle-invasive recurrence, regional lymph node recurrence or distant metastasis, over a given time period

    Time frame: When the eligible patients complete the treatment and followed-up for 1 and 2 years

  3. Disease-free survival (DFS)

    The percentage of the cases surviving without locoregional recurrence or distant metastasis over a given time period

    Time frame: When the eligible patients complete the treatment and followed-up for 1 and 2 years

  4. Local recurrence (LR) rate

    The percentage of the cases with locoregional recurrence over a given time period

    Time frame: When the eligible patients complete the treatment and followed-up for 1 and 2 years

  5. Incidence of grade 3/4 (G3/4) toxicities

    The percentage of the cases with any G3/4 toxicity during and after treatment

    Time frame: Once a week during treatment, and once per 3 months after treatment, until the last follow-up (2 years after treatment)

  6. Bladder function

    The quantitative score of bladder function at a given time point, based on the Quality of Life 30-item Questionnaire, Bladder Module (QLQ-BLM30) from the EORTC

    Time frame: Once per 3 months after treatment, until the last follow-up (2 years after treatment)

07

Study locations

1 site
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 36 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 3, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 30, 2026
Enrollment
71→64
Oct 30, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPretreatment clinical TNM stage as T2-4aN0M0 or T1-4aN14aN0-2M0 (UICC TNM staging classification, version 8)
Nov 3, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedObjective response rate (ORR)Time frame: A week before radiotherapy, and once per 3 months after treatment, until the last follow-up (2 years after treatment)
Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedObjective response rate (ORR)Time frame: A week before radiotherapy, and once per 3 months after treatment, until the last follow-up (2 years after treatment)
    + 2 other changes: verification date and arm descriptions
  2. Nov 3, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPretreatment clinical TNM stage as T2-4aN0M0 or T1-4aN14aN0-2M0 (UICC TNM staging classification, version 8)
  3. Oct 30, 2026
    Primary completion Dec 31, 2025→Dec 31, 2026
    Enrollment 71→64
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05975307
Responsible party
Yuan-hong Gao (Vice Director of the Department of Radiation Oncology, Cancer Center, Sun Yat-sen University) — Principal investigator
First posted
Aug 3, 2023
Start date
Dec 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Yuanhong Gao, MD
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Gemcitabine · Cisplatin · Carboplatin

Start the discussion